Literature DB >> 30203832

A phase 1/2, open-label, dose-escalation study of midostaurin in children with relapsed or refractory acute leukaemia.

C Michel Zwaan1,2, Stefan Söderhäll3,4, Benoit Brethon5, Matteo Luciani6, Carmelo Rizzari7, Ronald W Stam1,8, Emmanuelle Besse9, Catherine Dutreix9, Franca Fagioli10, Phoenix A Ho11, Carlo Dufour12, Rob Pieters8.   

Abstract

Entities:  

Keywords:  FLT3; acute leukaemia; midostaurin; paediatric; relapsed/refractory

Mesh：

Substances：

Year:  2018        PMID： 30203832     DOI： 10.1111/bjh.15593

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  4 in total

1.  Gilteritinib combination therapies in pediatric patients with FLT3-mutated acute myeloid leukemia.

Authors:  David McCall; Michael Roth; Kris M Mahadeo; Laurie Toepfer; Cesar Nunez; Nicholas J Short; Naval Daver; Tapan M Kadia; Courtney DiNardo; Joanna S Yi; Branko Cuglievan
Journal:  Blood Adv       Date:  2021-12-14

Review 2.  Targeted Therapies for Pediatric AML: Gaps and Perspective.

Authors:  Annalisa Lonetti; Andrea Pession; Riccardo Masetti
Journal:  Front Pediatr       Date:  2019-11-15       Impact factor: 3.418

Review 3.  Molecular-Targeted Therapy of Pediatric Acute Myeloid Leukemia.

Authors:  Piotr Obszański; Anna Kozłowska; Jakub Wańcowiat; Julia Twardowska; Monika Lejman; Joanna Zawitkowska
Journal:  Molecules       Date:  2022-06-18       Impact factor: 4.927

Review 4.  "FLipping" the Story: FLT3-Mutated Acute Myeloid Leukemia and the Evolving Role of FLT3 Inhibitors.

Authors:  Tristan E Knight; Holly Edwards; Soheil Meshinchi; Jeffrey W Taub; Yubin Ge
Journal:  Cancers (Basel)       Date:  2022-07-13       Impact factor: 6.575
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.